Comparative Pharmacology
Head-to-head clinical analysis: GABLOFEN versus OZOBAX DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GABLOFEN versus OZOBAX DS.
GABLOFEN vs OZOBAX DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
GABLOFEN (baclofen) is a GABA-B receptor agonist that reduces spinal reflex transmission and inhibits excitatory neurotransmitter release.
Baclofen, a gamma-aminobutyric acid (GABA) analog, acts as an agonist at GABA-B receptors in the spinal cord, leading to decreased excitatory neurotransmitter release and reduced muscle spasticity.
10 mg orally three times daily, may increase by 10 mg/day every 3 days to a maximum of 80 mg/day (20 mg four times daily).
Adults: 600 mg orally twice daily; if efficacy not achieved after 2–3 weeks, may increase to 600 mg three times daily.
None Documented
None Documented
Terminal half-life 5-7 hours; clinically relevant for dosing interval of every 6-8 hours.
Terminal elimination half-life is 1.0-1.5 hours in patients with normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 20-30 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% unchanged; biliary/fecal: <5% as metabolites. Total clearance 2.5-3.0 L/h.
Renal: 70-80% unchanged; fecal: 20-30%; biliary: <5%
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant